Polymorphism in HSD3B1 as a Potential Prognostic Biomarker in Prostate Cancer

Detection of a specific germline alteration in HSD3B1 may help oncologists gauge the potential benefit of upfront abiraterone or ADT in Japanese patients with prostate cancer.

from Latest articles from Cancer Therapy Advisor News https://ift.tt/2BNxIlU